[go: up one dir, main page]

EE200000321A - Uudsed ühendid - Google Patents

Uudsed ühendid

Info

Publication number
EE200000321A
EE200000321A EEP200000321A EEP200000321A EE200000321A EE 200000321 A EE200000321 A EE 200000321A EE P200000321 A EEP200000321 A EE P200000321A EE P200000321 A EEP200000321 A EE P200000321A EE 200000321 A EE200000321 A EE 200000321A
Authority
EE
Estonia
Prior art keywords
novel compounds
novel
compounds
Prior art date
Application number
EEP200000321A
Other languages
English (en)
Estonian (et)
Inventor
Baxter Andrew
Cheshire David
Mcinally Thomas
Mortimore Michael
Cladingboel David
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of EE200000321A publication Critical patent/EE200000321A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200000321A 1997-12-05 1998-12-01 Uudsed ühendid EE200000321A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704546A SE9704546D0 (sv) 1997-12-05 1997-12-05 Novel compounds
PCT/SE1998/002190 WO1999029686A1 (en) 1997-12-05 1998-12-01 Novel compounds

Publications (1)

Publication Number Publication Date
EE200000321A true EE200000321A (et) 2001-08-15

Family

ID=20409283

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000321A EE200000321A (et) 1997-12-05 1998-12-01 Uudsed ühendid

Country Status (16)

Country Link
EP (1) EP1037889A1 (xx)
JP (1) JP2001525406A (xx)
KR (1) KR20010032800A (xx)
CN (1) CN1284074A (xx)
AU (1) AU1791599A (xx)
BR (1) BR9813378A (xx)
CA (1) CA2312357A1 (xx)
EE (1) EE200000321A (xx)
HU (1) HUP0100731A3 (xx)
IL (1) IL136368A0 (xx)
NO (1) NO20002787L (xx)
PL (1) PL340837A1 (xx)
SE (1) SE9704546D0 (xx)
SK (1) SK8442000A3 (xx)
TR (1) TR200001544T2 (xx)
WO (1) WO1999029686A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901875D0 (sv) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
WO2004099146A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
RU2006146675A (ru) 2004-06-29 2008-07-10 Пфайзер Продактс Инк. (Us) Способ получения производных 5-[4-(2-гидроксипропил)-3,5-диоксо-4,5-дигидро-3н-[1,2,4] триазин-2-ил] бензамида снятием защиты с промежуточных продуктов, содержащих защищенный гидроксил
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為p2x7調節劑之雙環雜芳基化合物與其用途
MX2008011919A (es) 2006-03-16 2008-11-28 Renovis Inc Compuestos de bicicloheteroarilo como moduladores de p2x7 y usos de los mismos.
ES2569677T3 (es) 2006-03-16 2016-05-12 Second Genome, Inc. Compuestos bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
PL2049478T3 (pl) * 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
GB0613473D0 (en) * 2006-07-06 2006-08-16 Glaxo Group Ltd Novel compounds
CA2680275C (en) 2007-03-09 2016-08-23 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20100168171A1 (en) * 2007-03-28 2010-07-01 Paul John Beswick Piperidinone Carboxamide Derivatives as P2X7 Modulators
US20100144727A1 (en) * 2007-03-29 2010-06-10 Paul John Beswick Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators
WO2008119825A2 (en) 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
JP5506776B2 (ja) 2008-03-25 2014-05-28 アフェクティス ファーマシューティカルズ アーゲー 新規p2x7r拮抗薬及びその使用法
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
EA201201548A1 (ru) 2010-05-14 2013-05-30 Эффектис Фармасьютиклз Аг Новые способы получения p2x7r антагонистов
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP3713540B1 (en) 2017-11-21 2025-08-20 Solventum Intellectual Properties Company Plant based oil-in-water oral emulsions and methods of use
JP7341143B2 (ja) 2017-12-20 2023-09-08 スリーエム イノベイティブ プロパティズ カンパニー 口腔用組成物及び使用方法
US11324681B2 (en) 2017-12-20 2022-05-10 3M Innovative Properties Company Oral compositions and methods of use
CN113226287B (zh) 2018-12-29 2025-10-17 舒万诺知识产权公司 口腔制品及使用方法

Also Published As

Publication number Publication date
AU1791599A (en) 1999-06-28
HUP0100731A3 (en) 2002-08-28
SE9704546D0 (sv) 1997-12-05
KR20010032800A (ko) 2001-04-25
IL136368A0 (en) 2001-06-14
EP1037889A1 (en) 2000-09-27
JP2001525406A (ja) 2001-12-11
NO20002787D0 (no) 2000-05-31
SK8442000A3 (en) 2001-01-18
CN1284074A (zh) 2001-02-14
NO20002787L (no) 2000-08-01
WO1999029686A1 (en) 1999-06-17
PL340837A1 (en) 2001-02-26
HUP0100731A2 (hu) 2002-05-29
CA2312357A1 (en) 1999-06-17
TR200001544T2 (tr) 2000-11-21
BR9813378A (pt) 2000-10-10

Similar Documents

Publication Publication Date Title
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
IS5478A (is) Efnasambönd
IS5477A (is) Efnasambönd
EE200000321A (et) Uudsed ühendid
ID22850A (id) Senyawa-senyawa pirazina
IS5354A (is) Ný efnasambönd
NO994877D0 (no) Kalsilytiske forbindelser
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
EE9900448A (et) Ühendid
EE9900475A (et) Ühendid
NO996544D0 (no) Forbindelser
ID22983A (id) Senyawa-senyawa fluorometoksimino
EE9900466A (et) Ühendid
DE69737634D1 (de) Insektizide oxadiazinverbindungen
SE9702775D0 (sv) Novel compounds
SE9703735D0 (sv) Novel compounds
SE9704402D0 (sv) Novel compounds
SE9701099D0 (sv) Novel compounds
SE9702198D0 (sv) Novel compounds
SE9702199D0 (sv) Novel compounds
SE9701100D0 (sv) Novel compounds
SE9704403D0 (sv) Novel compounds
SE9702200D0 (sv) Novel compounds
SE9701098D0 (sv) Novel compounds